17岁男童反复腹痛、腹腔积液伴嗜酸性粒细胞增多

17岁男童，因腹痛、腹泻伴嗜酸性粒细胞增多3年，加重3 d入院。3年前患儿因进食“老酸奶”后出现腹痛、腹泻，彩超示大量腹腔积液，血常规、骨髓细胞形态学检查、腹水组织学检查可见大量嗜酸性粒细胞；3 d前因腹痛、腹泻再次入院，胃肠镜检查胃角见嗜酸性粒细胞浸润，确诊为嗜酸细胞性胃肠疾病（嗜酸细胞性胃肠炎），给予糖皮质激素及饮食规避治疗后好转，随访1年未反复。对于因腹痛、腹泻等消化道症状就诊的患儿，如伴外周血嗜酸性粒细胞增多，需考虑嗜酸细胞性胃肠疾病的可能，内镜活检胃肠道组织中见嗜酸性粒细胞浸润且计数异常为诊断的关键。 ［引用格式:中国当代儿科杂志，2021，23（11）：1169-1173］     

阿莫西林与替硝唑治疗急性肠胃炎的效果观察

目的观察阿莫西林与替硝唑治疗急性肠胃炎的效果。方法以本院2018年4月—2019年4月收治的60例急性肠胃炎患者作为研究对象,借助双盲随机抽样法分为对照、试验组,每组列入30例,对照组给予阿莫西林治疗,试验组予以阿莫西林与替硝唑联合治疗,评定两组患者的临床效果、肠胃炎症状积分。结果治疗前,两组患者的肠胃炎症状积分无显著差异,P>0.05(t=0.0752,P=0.9403);治疗后,试验组相较于对照组患者的肠胃炎症状积分较低,P<0.05(t=14.5841,P=0.0000);试验组(96.67%)较对照组(76.67%)临床效果较高,P<0.05(χ²=5.1923,P=0.0226)。结论急性肠胃炎患者予以阿莫西林与替硝唑联合治疗具有积极意义,值得临床研究。     

Identifying signatures of the impact of rotavirus vaccines on hospitalizations using sentinel surveillance data from Latin American countries

BackgroundPassive surveillance data are often the only available source of data that can be used to evaluate the population-level impact of vaccination, but such data often suffer from important limitations such as changes in surveillance efforts. This study provides an example of how to identify important signatures of rotavirus vaccine impact, including evaluating the overall effectiveness and changes in rotavirus seasonal dynamics.MethodsWe used data from a standardized sentinel rotavirus surveillance network in six Latin American countries (Bolivia, El Salvador, Guatemala, Honduras, Paraguay, and Venezuela) from 2004 to 2017. A random-effects model was used to evaluate changes in the proportion of rotavirus-associated hospitalizations following vaccine introduction. Harmonic regression models were used to estimate vaccine impact on the number of rotavirus hospitalizations, controlling for trends in rotavirus-negative cases. Changes to rotavirus seasonality were evaluated using center of gravity analysis, wavelet analysis, and harmonic regression.ResultsAll countries observed declines in the proportion of rotavirus-positive acute diarrhea samples with a mean reduction of 16% (95% confidence interval: 10–22%). We estimate that each 10% increase in vaccine coverage was associated with declines in the number of rotavirus-positive cases, ranging from 4.3% (1.3–7.2%) in Honduras to 21.4% (16.8–25.9%) in Venezuela. The strength of the seasonal peak in rotavirus incidence became smaller after vaccine introduction in Guatemala, Honduras, and Venezuela. Seasonal peaks also shifted later in the surveillance year, especially in higher-mortality countries.ConclusionsThe combination of methods we applied have different strengths that allow us to identify common signatures of rotavirus vaccine impact.     

儿童嗜酸性粒细胞性胃肠炎糖皮质激素治疗的预测因素分析

目的 分析儿童嗜酸性粒细胞性胃肠炎临床特点和治疗方案的关系，探讨糖皮质激素治疗的适用情况，为儿科医师选择治疗方案提供依据。 方法 回顾性收集广州市妇女儿童医疗中心2012年1月至2020年12月收治的182例嗜酸性粒细胞性胃肠炎患儿的临床资料。根据治疗方案中是否使用糖皮质激素分为激素组和对照组，比较分析两组患儿年龄、过敏史、临床症状、实验室检查结果、内镜下表现和胃肠黏膜病理结果，对差异有统计学意义的结果进一步行logistic回归分析。 结果 182例患儿中，36例使用糖皮质激素治疗，占总人数的19.8%。激素组患儿出现血便、贫血，内镜下出现黏膜溃疡/管腔狭窄的比例，以及黏膜嗜酸性粒细胞浸润计数均明显高于对照组（n=146，P<0.05）；激素组血清白蛋白水平明显低于对照组（P<0.05）。多因素logistic回归分析结果显示，内镜下见黏膜溃疡/管腔狭窄（OR=10.830，95%CI：3.090~37.961，P<0.001）和黏膜嗜酸性粒细胞浸润计数升高（OR=0.967，95%CI：0.941~0.993，P=0.015）可提示使用糖皮质激素治疗儿童嗜酸性粒细胞性胃肠炎。 结论 内镜下见到黏膜溃疡/管腔狭窄，病理显示黏膜嗜酸性粒细胞浸润计数明显升高，均提示儿童嗜酸性粒细胞性胃肠炎的治疗方案中可采用糖皮质激素治疗。 引用格式:     

A nano silicon adjuvant enhances inactivated transmissible gastroenteritis vaccine through activation the Toll-like receptors and promotes humoral and cellular immune responses

Inactivated transmissible gastroenteritis virus (TGEV) vaccines are widely used in swine herds in China. These are limited, however, by the need to elicit both humoral and cellular immunity, as well as the efficiency of adjuvants. In this study, a 70-nm nano silicon particle was applied with inactivated TGEV vaccine in mice, and its immune-enhancing effects and mechanism of action investigated. We found that nano silicon applied with inactivated TGEV vaccine induced high antibody titers, increase IL-6, TNF-α and IFN-γ expression, and stimulate CD3+ T cell proliferation with a high CD4+/CD8+ T lymphocyte ratio. Nano silicon could quickly activate innate and adaptive immunity by stimulating Toll-like receptor signaling pathways, indicating that the nano silicon adjuvant enhanced long-term humoral and early cellular immune responses when combined with inactivated TGEV vaccine. Nano silicon could be considered for use as an antigen- carrier and adjuvant for veterinary vaccines.     

Impact of rotavirus vaccine on acute gastroenteritis in children under 5 years in Senegal: Experience of sentinel site of the Albert Royer Children's Hospital in Dakar

BackgroundAcute gastroenteritis (AGE) is a leading cause of morbidity and mortality among children <5 years of age in developing countries, with rotavirus being the most common infectious etiology. In November 2014, monovalent rotavirus vaccine was introduced in Senegal. We determined the impact of rotavirus vaccine on hospitalizations for all-cause and rotavirus related AGE in children <60 months of age.MethodsWe examined two data sources from the national referral hospital. Using sentinel surveillance data from March 2011 to February 2017, we examined the proportion of AGE hospitalizations among children <60 months of age attributable to rotavirus, stratified by age groups (0–11, 12–23 and 24–59 months). Using pediatric logbook data from March 2010 to February 2017, we examined the proportion of all childhood hospitalizations attributable to AGE, among the same age groups.ResultsIn sentinel surveillance, 673 patients <60 months were hospitalized for AGE, with 30% (203/673) due to rotavirus. In pre-vaccine years, the median proportion of rotavirus-positive hospitalizations was 42%; this proportion declined by 76% to 10% rotavirus positive in 2015–2016 (p < .001) and by 59% to 17% in 2016–2017 (p < .001). From the logbook data, among all children <60 months, a median of 11% of all hospitalizations in the pre-vaccine period were due to AGE, with 2015–2016 seeing a 16% decline (p < .001), to 9% of all hospitalizations, and 2016–2017 seeing a 39% decline (p < .001), to 7% of all hospitalizations. Declines in both rotavirus-associated and all-cause AGE hospitalizations were most marked among infants, with a suggestion of herd effect among older children seen in the surveillance data.ConclusionRotavirus vaccine demonstrated a significant impact on rotavirus-associated hospitalizations and all-cause AGE hospitalizations in the first two seasons after vaccine introduction in Senegal. Our data support the continued use of this vaccine in national immunization program.     

Rotarix® and RotaTeq® administration to preterm infants in the neonatal intensive care unit: Review of available evidence

Rotavirus (RV) is the leading cause of severe acute gastroenteritis (GE) in infants worldwide. Several vaccines against RV were developed to reduce disease burden, hospitalization rates and health utilization costs. RV GE is a serious disease in preterm (PT) infants, and the administration of RV vaccine to these at-risk subjects at the proper time could have great clinical relevance. However, most data on the efficacy and safety of RV vaccinations were collected in healthy full-term infants, and few studies investigated PT infants. The lack of studies in PT infants may explain why neonatologists in several neonatal intensive care units (NICUs) do not follow the official recommendations, which indicate that RV vaccine may be administered in hospitals. Increasing neonatologists’ knowledge on the efficacy and safety of RV vaccines and defining PT candidates for vaccination and the necessary precautions are extremely important to avoid potential vaccine virus transmission and improve RV vaccination coverage in PT infants. Further studies should analyse the impact of vaccination of PT infants of different gestational ages and various clinical histories in stable conditions in the NICU with a careful monitoring of adverse events to the vaccine and RV GE occurrence. Only data that confirm the efficacy and safety of RV vaccines in large numbers of PT infants with different characteristics will convince neonatologists to use RV vaccines in PT infants hospitalized in NICUs.